CRISPR Therapeutics AG
CRSP
$41.86
$3.298.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -77.61% | -138.43% | 32.23% | 36.09% | 58.56% |
| Total Depreciation and Amortization | -2.33% | -2.91% | -7.05% | -6.58% | -15.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.23% | -28.42% | -28.21% | -38.00% | -41.01% |
| Change in Net Operating Assets | 103.14% | 180.72% | -9.97% | 290.03% | -139.49% |
| Cash from Operations | -92.24% | 45.17% | 31.99% | 64.50% | 54.67% |
| Capital Expenditure | 80.57% | 79.93% | 84.02% | 77.24% | 71.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -221.01% | -172.52% | -257.49% | -167.99% | 11,850.35% |
| Cash from Investing | -227.30% | -174.87% | -266.72% | -174.92% | 704.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.78% | 430.53% | 1,252.95% | 771.32% | 989.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.91% | 429.78% | 1,251.17% | 770.15% | 989.14% |
| Foreign Exchange rate Adjustments | 3.33% | -128.77% | 0.00% | -94.67% | 242.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -230.16% | -151.58% | -1,133.23% | 169.76% | 205.26% |